SCHEMBL18323669

SCHEMBL18323669

COCc1cc(CN2CCNCC2)cc2nnc(C)n12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 6/20 0.47
SIGMAR1 Q99720 1/20 0.36
CXCR4 P61073 6/20 0.36
CHEK1 O14757 2/20 0.34
CHRM2 P08172 2/20 0.34
MEN1 O00255 1/20 0.34
CHRM1 P11229 1/20 0.34
ADRA2C P18825 1/20 0.34
CCR2 P41597 1/20 0.34
CXCL12 P48061 1/20 0.34
BLM P54132 1/20 0.34
KMT2A Q03164 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
HRH3 Q9Y5N1 1/20 0.34
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
HPGD P15428 1/20 0.33
CYP1A2 P05177 1/20 0.33
SLC6A4 P31645 1/20 0.33
OPRD1 P41143 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18323613 0.86 BRD4 (0.50) BRD4SIGMAR1CXCR4CHEK1CHRM2
SCHEMBL18323599 0.86 BRD4 (0.37) BRD4SIGMAR1CXCR4CHEK1CHRM2
SCHEMBL18323630 0.82 BRD4 (0.49) BRD4SIGMAR1CXCR4CHEK1CHRM2
SCHEMBL18323615 0.82 BRD4 (0.47) BRD4SIGMAR1CXCR4CHEK1CHRM2
SCHEMBL14317627 0.82 BRD4 (0.56) BRD4SIGMAR1CXCR4CHEK1CHRM2
SCHEMBL14315483 0.80 BRD4 (0.51) BRD4SIGMAR1CXCR4CHEK1CHRM2
SCHEMBL18323668 0.78 BRD4 (0.47) BRD4SIGMAR1CXCR4CHEK1CHRM2
SCHEMBL18323600 0.78 BRD4 (0.49) BRD4SIGMAR1CXCR4CHEK1CHRM2
SCHEMBL18323611 0.77 BRD4 (0.48) BRD4SIGMAR1CXCR4CHEK1CHRM2
SCHEMBL18323610 0.76 BRD4 (0.47) BRD4SIGMAR1CXCR4CHEK1CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9522910-B2 Protein kinase inhibitors (variants), use thereof in treating oncological diseases and a pharmaceutical composition based thereon Obshchestvo s ogranichennoy otvetstvennostyou “Fusion Pharma” (RU) 2016-12-20 US disclosed